All In MedTech

Device Trial Radar · NCT07946679

Leveraging Telemedicine to Improve Guideline-Directed Medical Therapy Use and Outcomes Among Rural Patients With Heart Failure

Leveraging Telemedicine to Improve Guideline-Directed Medical Therapy Use and Outcomes Among Rural Patients With Heart Failure - the RURAL-HF Trial

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 600 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

600

Planned (sponsor's estimate)

Start

Dec 2026

Primary completion

Dec 2031

Study completion Dec 2031

Sponsor

Lead sponsor
University of MichiganAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 18, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if a new way of adjusting heart failure medicines can improve health in adults with heart failure who live in rural areas. This study tests whether remotely helping local doctors safely raise these doses faster can improve health over the first 3 months after leaving the hospital. The main questions it aims to answer are: * Does the new approach help participants live longer, avoid needing a heart transplant or heart pump, stay out of the hospital for heart failure, and feel better day to day, over 6 months? * Do more participants take all their recommended heart failure medicines, at the best doses, by 6 months? * Does the new approach improve quality of life and daily activity, and how well does it work in everyday rural health care? Participants will be placed by chance, like flipping a coin, into 1 of 2 groups: home monitoring alone or home monitoring plus medication optimization support. In the home monitoring alone group, participants' own doctors will manage their medicines as usual. In the medicine support group, heart failure specialists on the study team will use home readings and results from NT-proBNP blood tests, to send medicine advice to participants' own doctors. Researchers will compare the 2 groups to see if medicine support improves health and quality of life. Participants will: * Use a scale, blood pressure cuff, and activity tracker at home for 3 months * May have routine blood tests ordered by their own doctor about 2 and 6 weeks after joining, if they are in the medicine support group * Complete video or phone study visits when they join, at 3 months, and at 6 months * Answer questions about their heart failure symptoms and quality of life at each visit * Some participants may also be asked to take part in an interview about their experience.

Conditions

  • Heart Failure
  • Heart Failure Hospitalization

Interventions

  • Provider-to-provider telehealth GDMT titration supportOther

    The study team reviews remote monitoring data at least weekly, along with NT-proBNP and basic metabolic panel results from testing recommended at weeks 2 and 6 and obtained as part of routine clinical care. Recommendations for GDMT initiation and up-titration to optimal or maximally tolerated doses (drug, dose, titration schedule, and laboratory monitoring) are sent to the outpatient care team through the electronic health record every 1 to 2 weeks for 90 days, with at least one video or telephone consultation offered. A structured protocol integrating NT-proBNP, potassium, eGFR, blood pressure, and heart rate guides titration.

  • Cellular-connected remote patient monitoringDevice

    Participants receive a cellular-connected weight scale, blood pressure and heart rate monitor, and wrist-worn activity tracker that arrive pre-configured and require no home internet. Participants submit weight, heart rate, and blood pressure twice weekly for 6 weeks, then once weekly if no alerts occur. Step count is captured continuously. The study team reviews and actions alerts and contacts participants if no data are received for 7 days. Active monitoring continues for 90 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Hierarchical Composite of All-Cause Mortality, Heart Transplantation or Ventricular-Assist Device, Heart Failure Hospitalizations, and Improvement in Kansas City Cardiomyopathy Questionnaire ScoreTime frame: Baseline to 180 days

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • University of Michigan

    Ann Arbor, Michigan

  • Baylor Scott & White Cardiac Consultants - Plano

    Plano, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.